ドロップダウンアイコン
ドロップダウンアイコン
ドロップダウンアイコン
JP
/
EN
メニューアイコン
Press
Craif Launches Brain Check in Japan, an At-Home Urine Test for MCI and Dementia Risk
2026.11.16

The two-biomarker test distinguished people with mild cognitive impairment from healthy older adults with 90.0% sensitivity and 89.3% specificity in a 78-person study

TOKYO, November 13, 2026 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, today launched sales of Brain Check, part of its miSignal series, in Japan, a test that assesses a person's risk of mild cognitive impairment (MCI) and dementia from a urine sample collected at home and returned by mail.

"Craif's vision is a society in which people live out their full natural lifespan, and until now we have focused on the early detection of cancer, the leading cause of death in Japan. But living out a full lifespan is not only about living long. We believe it means living as yourself to the end and staying connected to the people who matter to you, and alongside cancer, dementia is something we need to take on to get there," said Ryuichi Onose, CEO of Craif.

Some people with MCI, the stage before dementia, return to normal cognitive function, making early detection and changing lifestyle habits important. Brain Check gives people a simple way to learn their risk at home, a reason to reassess their daily habits and, when needed, a prompt connection to a doctor. By supporting earlier awareness of MCI and dementia risk, Craif aims to help extend healthy life expectancy.

Brain Check extends the model Craif built for cancer detection. Since launching miSignal Scan, its urine test for cancer risk, in February 2022, Craif has refined the full testing experience, from ordering to support after results are delivered. miSignal is offered through more than 2,500 partner medical institutions and more than 4,700 pharmacies in Japan, and more than 110,000 samples have been tested across the miSignal series. Brain Check draws on this research and development experience in addition to the support Craif provides before and after testing.

Why early detection matters

As of 2022, about 4.43 million older adults in Japan were living with dementia and about 5.59 million with MCI, roughly 10 million in total. By 2040, those numbers are projected to reach about 5.84 million and 6.13 million. Each year, about 5% to 15% of people with MCI progress to dementia, while about 16% to 41% return to normal cognitive function.

The evidence for lifestyle change keeps building. In Finland, the FINGER trial showed that a combined program of diet, exercise, cognitive training and vascular risk management slowed cognitive decline, and a study built on the same approach, J-MINT, is under way in Japan. In 2024, the Lancet Commission on dementia reported that about 45% of dementia cases could potentially be prevented or delayed by addressing 14 modifiable risk factors, many of them tied to lifestyle. New treatments for MCI and mild dementia due to Alzheimer's disease have also reached patients in recent years, which makes early detection more valuable still. People need a way to learn their risk at home before symptoms appear, so they can adjust their habits and see a doctor when they need to.

Sources: Ministry of Health, Labour and Welfare research project, "Study on the Prevalence of Dementia and Mild Cognitive Impairment and Future Projections" (2024); National Center for Geriatrics and Gerontology, "MCI Handbook for a Healthy Mind and Body" (March 31, 2024); Ngandu T, et al. Lancet. 2015;385:2255-63 (FINGER trial); Livingston G, et al. Lancet. 2024;404:572-628 (Lancet Commission).

How Brain Check works

Brain Check measures two urinary biomarkers that reflect the state of the brain from different angles, neurodegeneration and oxidative stress, and analyzes them together.

The first, p75ECD (the extracellular domain of the p75 neurotrophin receptor), is a protein that changes as nerve cells degenerate. In Alzheimer's disease, amyloid beta is thought to begin building up in the brain years before symptoms such as forgetfulness appear. p75ECD is produced as nerve cells respond to these early changes and also appears in urine, which has drawn attention to it as a marker of brain changes at a stage people rarely notice themselves.

The second, 8-OHdG (8-hydroxy-2'-deoxyguanosine), forms when DNA is damaged by oxidation and reflects the body's level of oxidative stress. Oxidative stress is considered one of the factors involved in amyloid beta buildup and nerve cell damage. Because it can shift with lifestyle, regular testing can also help people see how changes to sleep, diet and exercise are showing up in the body.

By combining a marker tied to the brain's current state with a marker tied to risk that lifestyle can change, Brain Check assesses brain health from more than one angle. In a study of 78 people (28 healthy older adults, 20 patients with MCI and 30 patients with Alzheimer's disease), the test distinguished people with MCI from healthy older adults with a sensitivity of 90.0% and a specificity of 89.3%. Craif is presenting the results at the 45th Annual Meeting of the Japan Society for Dementia Research, held November 13 to 15, 2026, in Tsukuba, Japan.

"Dementia begins to change the brain years before symptoms appear. If people can notice it at the MCI stage, they can change their habits and work to maintain cognitive function. New treatment options have also emerged in recent years, and what it means to find dementia early is changing. Yet easy ways to get that early signal are still limited. Building on the technology we developed in cancer and our support for people before and after testing, we are taking on a new challenge: the early detection of dementia," added Onose.

Pricing and availability

Brain Check is now available for purchase in Japan through Craif's website and partner medical institutions. A single test costs 24,800 yen, and a subscription that retests every 12 months or every 6 months costs 19,800 yen per test, both including tax.

Customers who order online collect a urine sample at home and mail it to Craif's laboratory. A results report is mailed to them about one month after the sample is received and can also be viewed online. Patients submit their specimens directly at the medical facility where they undergo testing. Once processed, they will receive a report rating their risk as low, moderate or high and will suggest next steps based on the result. More information is available at misignal.jp/products/brain-check.

Brain Check is not a medical device. It determines risk through statistical calculations based on the information analyzed. It is not a substitute for a medical diagnosis of whether a person has MCI or dementia, and a low-risk result does not mean that MCI or dementia is absent or that a person will not develop MCI or dementia in the future.

Following the launch of its U.S. headquarters, Craif plans to bring Brain Check to the United States in the near future.

About miSignal Scan

miSignal Scan extracts microRNA from urine and analyzes it with AI to assess the risk of 10 cancer types, including pancreatic cancer, by individual cancer type and from stage 1.

miSignal Scan is not a medical device. It determines risk through statistical calculations based on the information analyzed. It is not a substitute for a medical diagnosis of whether a person has cancer, and a low-risk result does not mean that cancer is absent or that a person will not develop cancer in the future.

About Craif

Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.

Media inquiries

press_us@craif.com